logo
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity
Evidence of brain penetration, target engagement, and potential anti-seizure effects demonstrated through biomarkers for TMS-EMG and EEG
Safety and tolerability profile consistent with previously reported results for QRL-101
QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy
CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced positive topline data from QurAlis' Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101 in healthy volunteers evaluating biomarkers related to amyotrophic lateral sclerosis (ALS) and epilepsy.
Topline results demonstrated a dose-dependent, statistically significant decrease in motor nerve excitability threshold tracking (mNETT) strength-duration time constant (SDTC), the co-primary endpoint of the trial related to ALS. SDTC is a well-established electrophysiological biomarker of peripheral motor excitability related to ALS, where elevation of SDTC has been clinically shown to predict faster disease progression and mortality. The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 potassium channel opener ezogabine in a single-dose study in people with ALS. Additional observations for multiple secondary and exploratory endpoints related to motor nerve excitability were also significantly impacted.
The clinical trial demonstrated a statistically significant impact on multiple secondary and exploratory endpoints related to epilepsy. These included transcranial magnetic stimulation electromyography (TMS-EMG) intracortical facilitation which indicates effective inhibition of cortical excitability, as well as significant increases in electroencephalography (EEG) spectral power in beta and gamma spectral bands further demonstrating cortical target engagement and brain penetration. There was minimal to no impact on the slower delta and theta EEG bands, which suggests a low potential for GABA-A receptor activation and sedation. The study did not reach statistical significance on the co-primary endpoint of TMS-EMG motor evoked potential (MEP) amplitude, another measure of corticospinal excitability.
Results also demonstrated that the safety and tolerability profile of QRL-101 was consistent with previously reported study results evaluating QRL-101 to date. There were no serious adverse events or discontinuations due to adverse events reported observed in the study.
'We are excited by these topline data from our biomarker study in healthy participants which suggest that QRL-101 has the potential to provide a therapeutic effect for both ALS and epilepsy,' said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. 'Loss of Kv7.2/7.3 function from the mis-splicing of the KCNQ2 gene leading to hyperexcitability-induced neurodegeneration was one of the first genetic breakthroughs from human ALS motor neuron stem cell models made by our founders at Harvard. QurAlis was started to develop a best-in-class Kv7 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in about half of all people living with ALS. Elevated SDTC has been clinically linked to faster disease progression and mortality, underscoring the need for an effective treatment for this population.'
Dr. Roet continued, 'The decrease in SDTC observed with QRL-101 in this study was approximately 50% greater than previously reported for the Kv7 opener ezogabine in a single-dose study in people with ALS. QRL-101 has the potential to be a promising therapeutic, especially considering the encouraging results from a previous study with ezogabine in ALS patients showing positive effects on both SDTC and the disease progression biomarker compound muscle action potential (CMAP). Further, based on the strong clinical validation of Kv7.2/7.3 ion channel openers in seizure reduction, the TMS-EMG intracortical facilitation together with the EEG data from this study suggest QRL-101 may have the potential to reduce both frequency and severity of seizures in people living with epilepsy without causing sedation. We are encouraged by these results and look forward to advancing the clinical program for QRL-101 in both ALS and epilepsy so that we can fulfill our mission of bringing much-needed precision medicine options to patients.'
Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in both sporadic and genetic forms of ALS, with the majority caused by the mis-splicing of the KCNQ2 gene in the pre-mRNA. Kv7 is also a clinically validated target to regulate the hyperexcitable state in epilepsy. In vivo and in vitro studies have demonstrated that QRL-101 is more potent in threshold track studies and exhibits the potential for fewer clinical adverse events that ezogabine, a less selective, first-generation, Kv7.2/7.3 channel opener.
The Phase 1 PoM study (QRL-101-05, NCT06681441) was a randomized, double-blind, placebo-controlled, three-way crossover trial. The study was conducted at the Centre for Human Drug Research, an early-phase Contract Research Organization based in Leiden, The Netherlands. The study evaluated two dose levels of QRL-101 versus placebo in healthy volunteers, assessing:
Additional QRL-101 clinical trials include:
QRL-101-01 (NCT05667779) was a first-in-human, single-ascending dose clinical trial in 88 healthy participants. In this clinical trial, QRL-101 was shown to be well tolerated. The study completed in late 2023 and results from QRL-101-01 supported a tolerable dose range for subsequent studies.
QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy participants.
QRL-101-04 (NCT06714396) is a Phase 1 PoM single-dose, placebo-controlled clinical trial designed to evaluate the safety and tolerability of QRL-101 in people living with ALS. QRL-101-04 is expected to enroll approximately 12 participants with ALS and will evaluate the impact of QRL-101 on mNETT.
QRL-101-06 is a Phase 1 randomized, open-label, single dose, cross-over study to evaluate the PK of three formulations of QRL-101 in a fasted condition or in the presence of a high fat meal in healthy participants.
More information about the QRL-101 clinical trials can be found at www.clinicaltrials.gov.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Yahoo

time2 hours ago

  • Yahoo

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation
5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation

Yahoo

time8 hours ago

  • Yahoo

5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation

A record number of exhibitors and unprecedented investor participation defined this year's success. New business matchmaking milestones further elevated BEYOND Expo 2025. Fund at First Pitch, Innovation Awards, Founder Stage and Founders Club Among Key Initiatives Supporting Entrepreneurs from across Asia. MACAO, June 9, 2025 /PRNewswire/ -- The 5th BEYOND Expo concluded at The Venetian® Macao's Cotai with unprecedented momentum, cementing its role as a cornerstone for Asian tech innovation under the theme "Empowering Asia, Bridging the World." From inspiration by startups to wisdom shared by Alibaba Group's Chairman Joe Tsai, tech leaders and visionaries illustrated BEYOND Expo's commitment to supporting tech innovation in Asia. This year's BEYOND Expo attracted a record-breaking 25,000+ visitors, 800+ exhibitors, 300 media representatives, and over 800 investors, including more than 300 family offices and LPs, from over 120 countries — the highest numbers to date. Covering sectors from AI, Healthcare, Mobility, Property Tech, Clean Energy, Robotics, Fashion Tech, Sports Tech, to Web3, this year marked the largest and most content-rich BEYOND Expo to date. Beyond the breadth of industry focus, BEYOND Expo also deepened its commitment to regional collaboration through a series of forums spotlighting strategic markets such as Southeast Asia, Japan, the Middle East, Latin America, and Europe. This dual emphasis on sector innovation and regional opportunity positioned BEYOND Expo as one of the most prominent and impactful pan-Asian tech gatherings ever held. BEYOND Expo Co-Founder Dr. LU Gang said, "This year there has been a tremendous energy around BEYOND Expo, fueled by Asia's rapid rise in frontier technologies and a greater desire for inter-Asian collaboration and cooperation. The products and solutions on display demonstrate just how much AI is transforming so many aspects of our lives, from the food we eat and the clothes we wear to how we interact with each other. Our ecosystem partners, including media, investors, incubators, and suppliers, are driving this momentum and nurturing next-generation technologies." BEYOND Expo recognized some of these innovators by presenting 25 Innovation Awards and hosting competitions such as Fund at First Pitch (FAFP), which attracted 150 competitors. JumpStart Media Executive Chairman James Kwan chaired the 2025 FAFP finale, which featured three high profile investors as judges: Artest Management Group (AMG) Chairman, Metta World Peace; Gobi Partners Co-founder and Chairperson, Thomas Tsao, and Lingotto Innovation Managing Partner & Co-Head, Morgan Samet. BEYOND Expo Co-Founder Jason Ho added, "The impact of BEYOND Expo 2025 extends beyond the event itself. It has matured into a year-round ecosystem with the BEYOND Global Network and BEYOND Founders Club, initiatives that support the global expansion of Asian tech companies and foster knowledge and resource sharing among entrepreneurs, driving technological advancements to address global challenges." Most International Speaker Lineup and Dynamic Stage Experience in BEYOND's History During the three-day exhibition, BEYOND Expo delivered its most internationally diverse and intellectually stimulating content lineup ever. More than 300 speakers from across the globe, including Greater China, the United States, United Kingdom, Portugal, the Netherlands, Belgium, Brazil, Mexico, UAE, Singapore, Japan, South Korea, Thailand, Malaysia, Indonesia, Vietnam, Pakistan, and beyond, took the stage to share bold ideas and transformative insights. Seven thematic stages were strategically placed across the expo floor, offering an immersive and accessible experience for all attendees. From visionary keynotes to dynamic roundtables, these sessions spanned global trends and regional collaboration, across topics such as: Global Vision Summits: The BGlobal Summit, Global Investment Summit, Wealth Summit and Cross-Border E-commerce Ecosystem Forum explored how Asian innovators are scaling globally. Regional Collaboration Forums: Asia-Europe Tech Forum, Asia-Latam Tech Forum, ORIGIN Southeast Asia Conference, Japan Tech Forum, and the Zayed Sustainability Prize China Forum created rare opportunities for cross-regional partnerships and investment dialogues. Frontier Tech Spotlights: AI Summit, Web3 + AI Forum, Founders Talk, Transportation & Mobility Summit, Sports Tech Forum, Fashion Tech Forum, International Industrial Design Forum, and Gen Z Founder Forum brought cutting-edge conversations and industry innovation to the forefront. Women in Tech: The SheTech Summit championed greater representation and leadership for women in the tech ecosystem. This comprehensive summit program reinforced BEYOND Expo's status as a leading platform for driving innovation, collaboration, and growth in Asia's technology ecosystem. A Special Focus on Asia's Unicorn Founders The Opening Ceremony on May 21 convened some of the most influential minds in Asian tech to explore the theme "What's Next?". Among the featured speakers were Dr. Jian Wang, President of Zhejiang Lab and Founder of Alibaba Cloud; Carl Pei, Co-founder and CEO of Nothing; Dr. Burt Guo, CEO and Chief Scientist of Sichuan Aerofugia; Yuekai Zhao, Co-founder of Agile Robots SE; and Jingkang Liu, Founder of Insta360. A standout moment was the roundtable with unicorn founders, where these leaders exchanged bold ideas on scaling globally from Asia, a region rapidly emerging as the heartbeat of next-gen innovation. Building on that momentum, the two-day Founder Talk featured over 30 trailblazing founders driving breakthroughs in AI, robotics, consumer tech, and sustainability. The stage also welcomed over 25 rising stars at the Gen Z Founder Forum and Gen Z Awards Ceremony, where young innovators showcased tech-driven solutions to global challenges. From unicorn visionaries to next-generation disruptors, BEYOND Expo celebrated the full spectrum of entrepreneurial ambition shaping the future of Asia and beyond. Media Day Previewed BEYOND Expo 2025's Innovation Held ahead of the main exhibition, the Media Day welcomed Beyond Expo product showcases, Media Day facilitated meaningful exchanges between innovators and the global press, setting the stage for a high-impact expo with worldwide reach. A showcase for the tech-inspired products of the future BEYOND Expo showcased over 1,000 high-tech products, targeting daily lifestyle and sustainability solutions. These included biodegradable materials, enhanced earphones and speakers, smart eyewear, healthy food, humanoids, medical devices, robotic pets, sleeping aids, and future mobility solutions. B2B applications included AI-reality-inspired software, medical devices, energy-saving and industrial robots. Unmatched B2B Engagement and Industry Matchmaking For the first time, BEYOND Expo hosted multiple on-site business matchmaking sessions over three days, connecting key industry players. Major corporations such as China State Construction International, China Taiping, Sands China, CATL, Tokyu Land Corporation, BMW Group, Sony, Makuake, Mitsubishi Estate, and Panasonic participated, signaling strong demand for real-time, high-value engagement between corporates and innovators. These sessions provided both sides with an efficient platform to identify strategic partners and explore collaborative opportunities. International Delegations and Buyer Groups Expand Global Reach This year also saw the participation of numerous international delegations and "buyer groups," further amplifying BEYOND Expo's reach. Representatives from Deloitte China, BMW Group, Japanese buyer groups, Western crowdfunding platform executives, and prominent overseas influencers all engaged with exhibitors, many of whom reported valuable feedback and new partnership leads. BEYOND Expo was positioned as a global gateway for companies aiming to scale across Asia and beyond, while spotlighting the region's confidence and capacity in innovation. Backing the Region's Boldest Innovators BEYOND Expo further strengthened its commitment to supporting emerging companies with expanded programming tailored for startups. At the heart of Growth Park, a newly launched multi-purpose stage served as a high-impact arena for product unveilings, startup-focused events, and strategic partnership announcements. The Demo Stage, a headline feature of this space, gave rising tech companies the chance to debut their latest innovations in front of a global audience, including investors, media, and industry leaders. After Hours: Where Innovation Met Entertainment As day turned to night, BEYOND Expo 2025 transformed into a vibrant celebration where technology and culture seamlessly converged. Each evening featured exclusive events that blended immersive entertainment with meaningful networking opportunities. From Welcome Night and Gala Dinner to dynamic pool parties energized by live DJs, an electrifying performance by Jax Jones, and the breathtaking Cirque Le Soir circus spectacle, BEYOND Expo offered unforgettable experiences that extended the spirit of innovation well beyond the conference halls. BEYOND Expo 2025 Partners BEYOND Expo 2025 was made possible with the generous support of Strategic Partners China State Construction International Holdings Limited and China Taiping; Platinum Partners Taobao 88VIP and Macau Pass | MPay; Gold Partner Nam Kwong (Group) Company Limited; Sustainability Partner the Zayed Sustainability Prize; and Venue Partner Sands China Ltd. Additional partners included Asian Family Legacy Foundation, ChainNeXT, Design School of Hunan University, Founders Breakfast, Greenwich Economic Forum, GWA, MAP, INNOBAKER, IESt, Lushan Laboratory, ReGACY Innovation Group, RMI, Sherewires, SIEF, TNGlobal, wteam, and yehyehyeh. A full list of participating companies can be found here: BEYOND EXPO 2025 About BEYOND Expo The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia's leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions. BEYOND Expo has attracted participation from Asia's Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. View original content to download multimedia: SOURCE Beyond EXPO

EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI
EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI

Yahoo

time9 hours ago

  • Yahoo

EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI

LONDON, June 9, 2025 /PRNewswire/ -- EthicAI Advisory Limited ("EthicAI"), a University of Cambridge spinout and global leader in the ethical and responsible assurance of artificial intelligence, has launched a cloud-based AI assurance SaaS platform to address ethical and trust issues around the adoption of AI, unlocking the technology's economic potential. AI models can create problems across a number of areas: Fairness and bias — AI systems can discriminate against certain groups including through hidden bias in training data Transparency — automating workflows can create 'black box' issues where algorithmic decision-making is opaque and consequently hard to understand and challenge Employee impacts — automation may unintentionally disempower, not augment, human workers if not designed carefully. The adoption of AI without enablement and literacy programmes can also erode company culture and employee motivation BeehAIve® scrutinises models and datasets against 15 ethical dimensions, assessing evidence across thousands of measurement points. The platform allows organisations to design, deploy and monitor autonomous systems that are optimised for success. BeehAIve® allows for technical stress-testing of model performance to improve reliability, robustness and security, while also recommending ways to reduce energy usage from AI. The platform enables assessment of models and systems against regional and national legislation including the EU AI Act, GDPR, the Korean AI Act, as well as industry-specific regulations and globally recognised AI standards. BeehAIve® then recommends how gaps can be filled, preparing for cross-border compliance while building stakeholder trust. The platform offers organisations a secure hub for their AI data, ensuring information remains safe and encrypted at all times. Tanya Goodin, Founder & CEO of EthicAI says: "BeehAIve® is a unique platform that enables organisations and their stakeholders to adopt AI with increased trust and confidence. Research shows that consumer confidence in AI has fallen by 8% globally over the past five years due to concerns about how AI is designed and built. BeehAIve® looks under the hood of organisations' AI models and systems — both in development and post deployment — to identify blind spots and weaknesses and provides actionable insights on how to mitigate and manage risks." For further information, contact: tanya@ or tim@ EthicAI Advisory Ltd EthicAI was formed in 2022 to build trust in AI by assuring models and systems to the highest ethical and responsible standards. EthicAI spun out of the University of Cambridge's Leverhulme Centre for the Future of Intelligence, with all the founding team previously engaged in cutting-edge AI ethics research at the university. The founders' leadership experience spans organisations including the BBC, Fidelity Investments, Barclays, Merrill Lynch, Deutsche Bank and UBS. Read more about the team here. EthicAI's cloud-based platform BeehAIve® will allow the company to scale its offer, and bring solutions to more organisations, more rapidly. It sits at the heart of the company's mission to ensure the ethical and responsible adoption of state-of-the-art AI systems — powering their success and helping to strengthen the UK's position as a leader in artificial intelligence. View original content: Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store